News

COVID-19 and AI: An editorial review in EMBO from Michael B. Schultz, Daniel Vera, David A. Sinclair

In early January, responding to the escalating global health crisis, BenevolentAI experts deployed our technology to identify approved drugs that could be used to treat COVID-19. Using our AI tools and biomedical knowledge graph, the team uncovered baricitinib, an approved rheumatoid arthritis drug owned by Eli Lilly, as a potential treatment.


This discovery was made by exploring ways to inhibit the cellular processes that the virus uses to infect human cells. The aim was to identify existing medicines that could potentially stop the progression of COVID-19, inhibit the “cytokine storm” and reduce the inflammatory damage associated with this disease. The team hypothesised that baricitinib may also have antiviral properties, based on its predicted ability to inhibit two members of Numb-associated kinase (NAK) family, AAK1 and GAK.

The team believes that by blocking the virus and reducing inflammation in advanced-stage patients can help to save lives, as it is the severe inflammation that causes death meaning lungs fill with fluid and patients can no longer breathe.

In a recent publication in EMBO Molecular Medicine a team of international scientists from BenevolentAI, Eli Lilly, Karolinska and clinicians in Milan validate this artificial intelligence‐assisted prediction. Using liver organoids infected with SARS‐CoV‐2, they confirm dual antiviral and anti‐inflammatory activities. They also show disease improvement in four COVID‐19 patients who were given baricitinib, paving the way for more rigorous placebo‐controlled trials.

In this editorial comment, Michael B. Schultz, Daniel Vera and David Sinclair review these findings and explore the broader, longer-term implications of the AI-powered study on drug discovery: “Here, the marriage of machine learning and rapid clinical trials provides hope for progress, not only in today’s fight against COVID-19, but in the ongoing fight against acute and chronic diseases”.

Access the review in EMBO Molecular Medicine:

PUBLICATION


More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021